Increased Interferon-Induced Protein With Tetracopeptides () Reduces Mycobacterial Growth.

Abhilasha Madhvi, Hridesh Mishra, Novel N Chegou, Bienyameen Baker
Author Information
  1. Abhilasha Madhvi: DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  2. Hridesh Mishra: DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  3. Novel N Chegou: DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  4. Bienyameen Baker: DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Abstract

Objectives: The host immune response towards () is known to vary with the virulence of mycobacterial species. While the majority of exposed individuals develop latent TB infection (LTBI), a small proportion develops active TB disease. The milieu of understudied immune factors is believed to play an important role against host immune response towards mycobacteria. Here, we investigate the role of antiviral factors of the interferon-induced proteins with tetracopeptides () family, which, in our previous research, have shown to be upregulated in response to pathogenic , but as yet have no established role in host response to bacterial infections.
Methods: We performed vector-driven overexpression and siRNA-mediated downregulation of in THP-1 cells infected with different mycobacterial species. Also, we investigated the mRNA levels of in the LTBI and active-TB cases.
Results: Overexpression of reduces CFUs by ~32% (30%-43%) [Median (IQR)] across three different mycobacterial strains, while knock-down increases CFUs by ~57% (41%-78%). Compared to IFN-γ, treatment of infected THP-1 cells with IFN-β significantly increases the expression of , while the overexpression of had higher mRNA expression of IFN-β than IFN-γ. Cytokines like IDO-1, IL-6, IL-23, and IFN- γ are observed to play key roles in mycobacterial survival upon intervention. mRNA expression levels of were higher in LTBI cases as compared to active TB.
Conclusion: Higher expression levels of reduce survival of different drug-susceptible and drug-resistant mycobacteria and correlates with latent TB infection in infected individuals, hence emerging as an immuno-therapeutic target against .

Keywords

References

  1. Ann Transl Med. 2016 Nov;4(21):438 [PMID: 27942529]
  2. Cytokine. 2013 Feb;61(2):645-55 [PMID: 23299081]
  3. Cell Mol Immunol. 2020 Sep;17(9):901-913 [PMID: 32728204]
  4. Virulence. 2020 Dec;11(1):170-182 [PMID: 32052695]
  5. Immunol Res. 2011 Aug;50(2-3):202-12 [PMID: 21717066]
  6. Comp Immunol Microbiol Infect Dis. 2019 Dec;67:101355 [PMID: 31586851]
  7. PLoS Pathog. 2016 Aug 08;12(8):e1005809 [PMID: 27500737]
  8. PLoS One. 2014 Jun 20;9(6):e100015 [PMID: 24950240]
  9. Cell Rep. 2018 Oct 2;25(1):95-106.e6 [PMID: 30282041]
  10. J Vis Exp. 2010 May 12;(39): [PMID: 20467416]
  11. Nucleic Acids Res. 2015 Jan;43(Database issue):D1152-7 [PMID: 25392412]
  12. Pharmacol Ther. 2004 Sep;103(3):245-59 [PMID: 15464592]
  13. BMC Immunol. 2008 Dec 24;9:75 [PMID: 19108715]
  14. Nat Rev Mol Cell Biol. 2004 Oct;5(10):827-35 [PMID: 15459663]
  15. J Immunol. 2012 Jun 15;188(12):6205-15 [PMID: 22566567]
  16. Cytokine. 2010 Jul;51(1):42-6 [PMID: 20434357]
  17. Cell Biosci. 2018 Sep 29;8:52 [PMID: 30288253]
  18. J Viral Hepat. 2012 Dec;19(12):843-53 [PMID: 23121362]
  19. J Infect Dis. 2013 Apr 15;207(8):1253-61 [PMID: 23359591]
  20. Curr Opin Immunol. 2007 Aug;19(4):441-7 [PMID: 17702558]
  21. Int J Mol Sci. 2017 Dec 16;18(12): [PMID: 29258190]
  22. J Immunol. 2013 Oct 1;191(7):3913-21 [PMID: 24014876]
  23. PLoS One. 2016 Apr 07;11(4):e0153079 [PMID: 27055235]
  24. J Virol. 2015 Mar;89(5):2462-8 [PMID: 25428874]
  25. J Infect Dis. 2018 Aug 14;218(6):1000-1008 [PMID: 29767733]
  26. Wiley Interdiscip Rev RNA. 2011 Mar-Apr;2(2):277-98 [PMID: 21957010]
  27. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8 [PMID: 9861020]

MeSH Term

Antigens, Bacterial
Antiviral Agents
Cytokines
Humans
Interferon-gamma
Interferons
Latent Tuberculosis
Mycobacterium tuberculosis
RNA, Messenger
Tuberculosis

Chemicals

Antigens, Bacterial
Antiviral Agents
Cytokines
RNA, Messenger
Interferon-gamma
Interferons

Word Cloud

Created with Highcharts 10.0.0responsemycobacterialTBLTBIexpressionhostimmunerolemycobacteriainfecteddifferentmRNAlevelstowardsspeciesindividualslatentinfectionactivefactorsplayoverexpressionTHP-1cellscasesCFUsknock-downincreasesIFN-γIFN-βhighersurvivalObjectives:knownvaryvirulencemajorityexposeddevelopsmallproportiondevelopsdiseasemilieuunderstudiedbelievedimportantinvestigateantiviralinterferon-inducedproteinstetracopeptidesfamilypreviousresearchshownupregulatedpathogenicyetestablishedbacterialinfectionsMethods:performedvector-drivensiRNA-mediateddownregulationAlsoinvestigatedactive-TBResults:Overexpressionreduces~32%30%-43%[MedianIQR]acrossthreestrains~57%41%-78%ComparedtreatmentsignificantlyCytokineslikeIDO-1IL-6IL-23IFN-γobservedkeyrolesuponinterventioncomparedConclusion:Higherreducedrug-susceptibledrug-resistantcorrelateshenceemergingimmuno-therapeutictargetIncreasedInterferon-InducedProteinTetracopeptidesReducesMycobacterialGrowthIFITtuberculosis

Similar Articles

Cited By